Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login
Market Place

Information, Expiry & Status of Health Canada Patents covering Rufinamide.

Client Email

Product

Rufinamide
HEALTH CANADA PATENTS

Renejix: CDMO with expertise in small molecule oral dosage, delivery tech, and multi-modality manufacturing.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Rufinamide

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

14 API Suppliers, 9 USDMF, 2 EU WC, 8 NDC API, 9 Listed Suppliers, $ API Reference Price

14 API Suppliers
9 USDMF
2 EU WC
8 NDC API
9 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports

API Reference Price
API Exports
API Imports

INTERMEDIATES

2 API Suppliers

2 API Suppliers

FINISHED DOSAGE FORMULATIONS

46 FDF Dossiers, 26 FDA Orange Book, 15 Europe, 5 Canada

46 FDF Dossiers
26 FDA Orange Book
15 Europe
5 Canada

DRUG PRODUCT COMPOSITIONS

SUSPENSION;ORAL - 40MG/ML, TABLET;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 200MG, TABLET;ORAL - 400MG

SUSPENSION;ORAL - 40MG/ML
TABLET;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 200MG
TABLET;ORAL - 400MG

RELATED EXCIPIENT COMPANIES

2 Rochem International Inc, 7 SPI Pharma, 2 Seqens, 7 DKSH, 11 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 1 ACG Worldwide, 3 Actylis, 1 Aeon Procare, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 15 BASF, 10 Corel Pharma Chem, 4 DFE Pharma, 2 Finar, 6 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 29 Kerry, 4 Kima Chemical, 6 Lonza Capsugel, 13 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 4 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 24 Roquette, 7 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 3 The Dow Chemical Company, 1 Valens Pharmachem, 2 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

58 Fillers, Diluents & Binders, 49 Coating Systems & Additives, 28 Direct Compression, 27 Thickeners and Stabilizers, 26 Controlled & Modified Release, 18 Film Formers & Plasticizers, 16 Granulation, 15 Lubricants & Glidants, 15 Topical, 14 Co-Processed Excipients, 13 Taste Masking, 11 Disintegrants & Superdisintegrants, 11 Solubilizers, 8 Rheology Modifiers, 8 Chewable & Orodispersible Aids, 7 Parenteral, 6 Emulsifying Agents, 5 Empty Capsules, 4 Vegetarian Capsules, 4 API Stability Enhancers, 4 Coloring Agents, 1 Soft Gelatin, 1 Surfactant & Foaming Agents

58 Fillers, Diluents & Binders
49 Coating Systems & Additives
28 Direct Compression
27 Thickeners and Stabilizers
26 Controlled & Modified Release
18 Film Formers & Plasticizers
16 Granulation
15 Lubricants & Glidants
15 Topical
14 Co-Processed Excipients
13 Taste Masking
11 Disintegrants & Superdisintegrants
11 Solubilizers
8 Rheology Modifiers
8 Chewable & Orodispersible Aids
7 Parenteral
6 Emulsifying Agents
5 Empty Capsules
4 Vegetarian Capsules
4 API Stability Enhancers
4 Coloring Agents
1 Soft Gelatin
1 Surfactant & Foaming Agents

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 21 NEWS #PharmaBuzz

1 DATA COMPILATION #PharmaFlow
21 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 15 Finished Drug Prices, 13 Annual Reports

2 US Medicaid Prescriptions
15 Finished Drug Prices
13 Annual Reports

MARKET PLACE

1 APIs

1 APIs

PATENTS & EXCLUSIVITIES

4 Health Canada Patents

4 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 USP, 3 Others

3 USP
3 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 1,847 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

4 All

01 4Eisai Limited

filter Patent Reset all filters

4 All

01 42256013

filter Product Reset all filters

4 All

01 4Rufinamide

filter Dosage Reset all filters

4 All

01 1Suspension

02 2Tablet

03 1Tablets

filter Exp Date Reset all filters

4 All

01 42018-06-08

Product Main Page

01

Eisai Limited

Rufinamide

AAPS 2024

Not Confirmed

Eisai Limited

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2018-06-08

Date Granted : 2007-10-16

Brand Name : BANZEL

Patent Number : 2256013

Filing Date : 1998-06-08

Strength per Unit : 40 mg / mL

Dosage Form : Suspension

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2018-06-08

Date Granted : 2007-10-16

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Eisai Limited

Rufinamide

AAPS 2024

Not Confirmed

Eisai Limited

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2018-06-08

Date Granted : 2007-10-16

Brand Name : BANZEL

Patent Number : 2256013

Filing Date : 1998-06-08

Strength per Unit : 100 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2018-06-08

Date Granted : 2007-10-16

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Eisai Limited

Rufinamide

AAPS 2024

Not Confirmed

Eisai Limited

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2018-06-08

Date Granted : 2007-10-16

Brand Name : BANZEL

Patent Number : 2256013

Filing Date : 1998-06-08

Strength per Unit : 200 mg

Dosage Form : Tablets

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2018-06-08

Date Granted : 2007-10-16

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

Eisai Limited

Rufinamide

AAPS 2024

Not Confirmed

Eisai Limited

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2018-06-08

Date Granted : 2007-10-16

Brand Name : BANZEL

Patent Number : 2256013

Filing Date : 1998-06-08

Strength per Unit : 400 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2018-06-08

Date Granted : 2007-10-16

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?